Work

Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease

Year: 2018

Type: article

Study design: Clinical Trial

Abstract: Key Points Annual rates of respiratory illness in sickle cell disease decreased by >50% during the second year of monthly doses of oral vitamin D3. Reduction in rates was similar with high-dose (100 000 IU/mo) and standard-dose (12 000 IU/mo) treatment.

Source: Blood Advances

DOI: 10.1182/bloodadvances.2017013979

Authors: Margaret T. Lee, Meyer Kattan, Ilene Fennoy, Stephen M. Arpadi, Rachel L. Miller, Serge Cremers, Donald J. McMahon, Jeri W. Nieves, Gary M. Brittenham

Institutions: Columbia University Irving Medical Center, Columbia University

Language: English

Topic: Hemoglobinopathies and Related Disorders

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,800

Funders: National Institutes of Health, U.S. Food and Drug Administration, National Center for Advancing Translational Sciences

Awards: G1326316569, G7057963024, Clinical and Translational Science Award, G9000303460

OpenAlex ID: W2801790576

FWCI: 2.406

Cites: 61

Cited by: 36

Related to: 10